AbbVie Pounces On Chance To Buy Revenues In $63bn Mega-Deal For Allergan
Executive Summary
AbbVie will gain the $3.58bn Botox business, a women's health franchise and gastrointestinal products in an opportunistic acquisition intended to reduce the company's dependence on Humira.
You may also be interested in...
Novartis Slips Into Pfizer's Number One Pharma Slot Amid Leaderboard Shakeup
Pfizer has dropped to number seven in our top pharma rankings after a long reign. AbbVie has risen to number three, growing through merger expansion.
AbbVie Ready To Leverage Migraine Franchise In Crowded Market
The US FDA approved the oral CGRP inhibitor Qulipta (atogepant) for migraine prevention, making AbbVie the only company with three drugs for three different migraine indications.
AbbVie Pushes Greater Flexibility With Oral Migraine Preventative Atogepant
With an FDA approval decision for preventing episodic migraines expected during Q3, atogepant would add an oral CGRP antagonist to classmate Ubrelvy for acute attacks and Botox for prevention of chronic episodes.